1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 12,100 | 12,300 | 22:19 | |
| 11,900 | 12,400 | 22:01 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 03.04. | MiNK Therapeutics and Memorial Sloan Kettering to Present Phase II Study of agenT-797 Combination in PD-1 Refractory Gastroesophageal Cancer at AACR 2026 | 1 | GlobeNewswire (USA) | ||
| 02.04. | MiNK Therapeutics to Present New Data at ASGCT 2026 Highlighting Context-Dependent Activity of iNKT Cell Therapy | 3 | GlobeNewswire (USA) | ||
| 31.03. | MiNK Therapeutics, Inc. - 10-K, Annual Report | - | SEC Filings | ||
| 31.03. | MiNK Therapeutics GAAP EPS of -$0.56 beats by $0.12 | 6 | Seeking Alpha | ||
| 31.03. | MiNK Therapeutics Reports Q4 and Full Year 2025 Results; Phase 2 Programs Advance with Impactful Non-Dilutive Momentum | 178 | GlobeNewswire (Europe) | ARDS / hypoxemic pneumonia Phase 2 trial initiation 1H 2026; early data by year end; market opportunity of ~200,000-300,000 patients annually in US/EUC-Further Consortium collaboration adds to growing... ► Artikel lesen | |
| 27.03. | MiNK Therapeutics: Aktie springt nach Klarstellung zu Gesprächen über Kombinationsstudien | 8 | Investing.com Deutsch | ||
| MINK THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 27.03. | MiNK Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 19.03. | MiNK Therapeutics, Inc. - 8-K, Current Report | 6 | SEC Filings | ||
| 17.03. | MiNK Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Highlight Platform Expansion Across iNKT Cell Therapy Programs | 1 | GlobeNewswire (USA) | ||
| 11.03. | Why Is MiNK Therapeutics Stock Trading Lower On Wednesday? | 7 | Benzinga.com | ||
| 10.03. | MiNK Therapeutics Pediatric Cancer Breakthrough Sparks Stock Rally | 2 | Benzinga.com | ||
| 10.03. | Morning Market Movers: MiNK Therapeutics, Garden Stage, Arq, Inc., SciSparc See Big Swings | 559 | AFX News | BEIJING (dpa-AFX) - At 8:05 a.m. ET on Tuesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| 10.03. | MiNK Therapeutics rockets 60% after collaboration with C-Further for pediatric cancers | 6 | Seeking Alpha | ||
| 10.03. | MiNK Therapeutics Announces Collaboration with C-Further to Advance PRAME-Targeted iNKT Cell Therapy for Pediatric Cancers | 4 | GlobeNewswire (USA) | ||
| 04.02. | MiNK Therapeutics Presents New Data of allo-iNKT Cell Therapy as a Potential Disease-Modifying Approach in Idiopathic Pulmonary Fibrosis at Keystone Symposia | 1 | GlobeNewswire (USA) | ||
| 08.01. | MiNK Therapeutics and University of Wisconsin-Madison Announce Phase 1 Clinical Trial of Allo-iNKT Cell Therapy (AgenT-797) to Evaluate Prevention of Graft-Versus-Host Disease | 340 | GlobeNewswire (Europe) | Non-dilutive public-private funded trial with NIAID STTR & Mary Gooze Clinical Trial and Translation AwardExpands iNKT platform into transplantation with an off-the-shelf, HLA-independent, lymphodepletion-free... ► Artikel lesen | |
| 02.01. | MiNK Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 08.12.25 | MiNK Therapeutics, Inc. - 8-K, Current Report | 7 | SEC Filings | ||
| 20.11.25 | MiNK Therapeutics Announces New Data Showing MiNK-215 Drives Potent Anti-Tumor Activity in Treatment-resistant Solid Tumors | 1 | GlobeNewswire (USA) | ||
| 14.11.25 | MiNK Therapeutics GAAP EPS of -$0.65 beats by $0.20 | 2 | Seeking Alpha |
1 2 Weiter >>
29 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 86,75 | +2,91 % | BioNTech-Aktie: Wann geht's wieder über 100 Euro? | BioNTech hat neue klinische Daten zu einem wichtigen Krebsmedikament veröffentlicht und damit erneut Fortschritte in seiner Onkologie-Pipeline demonstriert. Für Investoren sind solche Studiendaten entscheidend... ► Artikel lesen | |
| BB BIOTECH | 49,950 | -0,70 % | Dividenden als Portfolio-Anker: Alte Bekannte Sanofi und BB Biotech - Geheimtipp RE Royalties | In einem Marktumfeld, das von strukturellen Umbrüchen geprägt ist, rückt die Stabilität des Portfolios in den Fokus. Analysten von J.P. Morgan betonen, dass der Schutz von Buchgewinnen der vergangenen... ► Artikel lesen | |
| OCUGEN | 1,646 | -0,12 % | Ocugen Announces Early Completion of Dosing in Phase 2/3 Pivotal Confirmatory Trial of OCU410ST for Stargardt Disease | GARDian3 trial enrollment and dosing completed (N=63) in less than nine monthsTopline results expected in 2Q27 with BLA to follow by mid-2027OCU410ST represents a potential first-in-class, one-time... ► Artikel lesen | |
| VIKING THERAPEUTICS | 30,100 | +0,17 % | Viking Therapeutics, Inc.: Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-2 Trial of VK2735 | 78-Week Study Evaluating Subcutaneous VK2735 in Adults with Obesity and Type 2 Diabetes
SAN DIEGO, March 26, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking)... ► Artikel lesen | |
| EDITAS MEDICINE | 2,840 | -0,35 % | Editas Medicine, Inc.: Editas Medicine Announces U.S. Patent and Trademark Office Reaffirms its Prior Decision in Favor of the Broad Institute in CRISPR/Cas9 Interference | CAMBRIDGE, Mass., March 27, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today... ► Artikel lesen | |
| SAREPTA THERAPEUTICS | 17,800 | -3,37 % | Sarepta/Roche Duchenne therapy to face new late-stage trial targeting EU nod | ||
| GERON | 1,457 | +1,43 % | Geron Corporation: Geron Announces Appointment of Timothy Williams as Executive Vice President, Chief Legal Officer and Corporate Secretary | FOSTER CITY, Calif., April 13, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer... ► Artikel lesen | |
| BASILEA | 60,00 | -2,60 % | Basilea Pharmaceutica International Ltd, Allschwil: Basilea erhält zusätzliche USD 6 Mio. von CARB-X für die klinische Entwicklung des Antibiotikums BAL2420 | Zusage der finanziellen Förderung nach erfolgreichem Abschluss präklinischer Studien und Erhalt der Genehmigung zur Durchführung klinischer Studien Zusätzliche USD 6 Mio. für die erstmalige Erprobung... ► Artikel lesen | |
| MICROBOT MEDICAL | 2,120 | +4,43 % | Microbot Medical stellt auf der Needham Healthcare Conference vor | ||
| TELIX PHARMACEUTICALS | 9,299 | +1,46 % | Telix Pharmaceuticals Limited: Telix Doses First Patient in Phase 3 IPAX-BrIGHT Trial of TLX101-Tx for Recurrent Glioblastoma | MELBOURNE, Australia and INDIANAPOLIS, April 15, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces that the first patient has been dosed with... ► Artikel lesen | |
| REPLIGEN | 111,06 | +0,67 % | Repligen Corporation: Repligen Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Financial Guidance | Fourth quarter revenue of $198 million, a year-over-year increase of 18% as reported, 14% organic with continued momentum in orders in the quarterFull year 2025 revenue of $738 million, a year-over-year... ► Artikel lesen | |
| NOVOCURE | 9,700 | -5,92 % | Novocure: Uri Weinberg erhält Gehaltserhöhung für neue Doppelrolle | ||
| CYTOMX THERAPEUTICS | 4,193 | +8,60 % | CytomX-Aktie: sharedealsPlus-Highflyer schießt auf +1.835% Kursgewinn | Die Aktie von CytomX Therapeutics gehört weiterhin zu den spektakulärsten Turnaround-Stories im Biotech-Sektor. Seit ihrem Vorjahrestief hat sich der Kurs des sharedealsPlus-Tipps inzwischen um rund... ► Artikel lesen | |
| UNIQURE | 13,880 | -5,19 % | Bronstein, Gewirtz & Grossman, LLC: Bronstein, Gewirtz & Grossman LLC Urges uniQure N.V. Investors to Act: Class Action Filed Alleging Investor Harm | New York, New York--(Newsfile Corp. - April 13, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed... ► Artikel lesen | |
| OXFORD NANOPORE TECHNOLOGIES | 1,385 | +2,90 % | Oxford Nanopore Tech - Director/PDMR Shareholding - LTIP and DBP awards |
MINK THERAPEUTICS INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 11,200 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MINK THERAPEUTICS INC finden Sie auf Wallstreet Online.